2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Physicians report Vimpat ® is the add-on of choice for epilepsy<br />
patients and is being used earlier in the treatment algorithm<br />
Share of NWRx<br />
30%<br />
25%<br />
20%<br />
15%<br />
10%<br />
5%<br />
0%<br />
Physicians report: Vimpat ® Physicians report: Vimpat is the<br />
agent of choice when selecting an<br />
add-on therapy for epilepsy<br />
® is the<br />
agent of choice when selecting an<br />
add-on therapy for epilepsy<br />
12/09<br />
n=403<br />
1/10<br />
405<br />
2/10<br />
388<br />
3/10<br />
407<br />
Source: Impact Rx and Dec <strong>2010</strong> ATU<br />
4/10<br />
374<br />
5/10<br />
389<br />
6/10<br />
403<br />
7/10<br />
419<br />
8/10<br />
408<br />
9/10<br />
374<br />
10/10<br />
359<br />
11/10<br />
330<br />
12/10<br />
318<br />
Vimpat<br />
Keppra<br />
Lamictal<br />
Keppra XR<br />
Lamictal XR<br />
17
Change language